Assessing Whether Moderna Inc (NASDAQ: MRNA) Is Over- Or Undervalued

Moderna Inc (MRNA) concluded trading on Wednesday at a closing price of $101.21, with 5.16 million shares of worth about $522.73 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -2.03% during that period and on April 3, 2024 the price saw a loss of about -2.32%. Currently the company’s common shares owned by public are about 382.00M shares, out of which, 336.22M shares are available for trading.

Stock saw a price change of -5.77% in past 5 days and over the past one month there was a price change of 5.43%. Year-to-date (YTD), MRNA shares are showing a performance of 1.77% which decreased to -34.10% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $62.55 but also hit the highest price of $163.24 during that period. The average intraday trading volume for Moderna Inc shares is 4.20 million. The stock is currently trading -3.54% below its 20-day simple moving average (SMA20), while that difference is up 1.86% for SMA50 and it goes to 1.03% higher than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Moderna Inc (NASDAQ: MRNA) currently have 382.00M outstanding shares and institutions hold larger chunk of about 66.31% of that.

The stock has a current market capitalization of $38.75B and its 3Y-monthly beta is at 1.59. It has posted earnings per share of -$12.41 in the same period. It has Quick Ratio of 3.36 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MRNA, volatility over the week remained 5.14% while standing at 4.55% over the month.

Analysts are in expectations that Moderna Inc (MRNA) stock would likely to be making an EPS of -$3.45 in the current quarter, while forecast for next quarter EPS is -$3.5 and it is -$5.19 for next year. For the current quarter EPS, analysts have given the company a lowest target -$4.32 which is -$1.94 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.19 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 41.66% while it is estimated to increase by 27.60% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by HSBC Securities on February 26, 2024 offering a Reduce rating for the stock and assigned a target price range of between $75 and $86 to it. Coverage by Oppenheimer stated Moderna Inc (MRNA) stock as an Outperform in their note to investors on January 02, 2024, suggesting a price target of $142 for the stock. On November 29, 2023, Canaccord Genuity Initiated their recommendations, while on November 03, 2023, HSBC Securities Upgrade their ratings for the stock with a price target of $69. Stock get a Sell rating from Deutsche Bank on November 02, 2023.

Most Popular

Related Posts